Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Inspira Technologies Oxy BHN ( (IINN) ).
On August 19, 2025, Inspira Technologies announced a $27 million binding purchase order from a national ministry of health in Africa for its FDA-cleared ART100 systems. This order, secured through Inspira’s distribution partner, marks a strategic breakthrough, validating the company’s commercial model and accelerating revenue. The ART100 systems have been chosen for their proven performance in Tier-1 hospitals in the U.S., and the order contributes to Inspira’s total secured binding purchase orders for 2025, amounting to $49.5 million. Deliveries and installations are scheduled throughout 2025, reinforcing the company’s momentum and commitment to stakeholders.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company offers the FDA-cleared INSPIRA ART100 system, designed for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. It is also developing the INSPIRA ART500, a next-generation system for oxygenation while patients remain awake. Additionally, Inspira is advancing its HYLA blood sensor platform for continuous, non-invasive monitoring. The company is strategically positioned within the life-support and MedTech landscape, with a focus on innovation and potential strategic partnerships.
Average Trading Volume: 910,642
Technical Sentiment Signal: Buy
Current Market Cap: $32.54M
For an in-depth examination of IINN stock, go to TipRanks’ Overview page.